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Abstract
Background: Cigarette smoke is a major risk factor for chronic obstructive pulmonary disease (COPD), an
inflammatory lung disorder. COPD is characterized by an increase in CD8
+ T cells within the central and peripheral
airways. We hypothesized that the CD8
+ T cells in COPD patients have increased Toll-like receptor (TLR) expression
compared to control subjects due to the exposure of cigarette smoke in the airways.
Methods: Endobronchial biopsies and peripheral blood were obtained from COPD patients and control subjects.
TLR4 and TLR9 expression was assessed by immunostaining of lung tissue and flow cytometry of the peripheral
blood. CD8
+ T cells isolated from peripheral blood were treated with or without cigarette smoke condensate (CSC)
as well as TLR4 and TLR9 inhibitors. PCR and western blotting were used to determine TLR4 and TLR9 expression,
while cytokine secretion from these cells was detected using electrochemiluminescence technology.
Results: No difference was observed in the overall expression of TLR4 and TLR9 in the lung tissue and peripheral
blood of COPD patients compared to control subjects. However, COPD patients had increased TLR4 and TLR9
expression on lung CD8
+ T cells. Exposure of CD8
+ T cells to CSC resulted in an increase of TLR4 and TLR9 protein
expression. CSC exposure also caused the activation of CD8
+ T cells, resulting in the production of IL-1b, IL-6, IL-10,
IL-12p70, TNFa and IFNg. Furthermore, inhibition of TLR4 or TLR9 significantly attenuated the production of TNFa
and IL-10.
Conclusions: Our results demonstrate increased expression of TLR4 and TLR9 on lung CD8
+ T cells in COPD. CD8
+
T cells exposed to CSC increased TLR4 and TLR9 levels and increased cytokine production. These results provide a
new perspective on the role of CD8
+ T cells in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide [1],
with more than 80% of COPD cases caused by cigarette
smoking [2]. Chronic inflammation observed in COPD
is characterized by pro-inflammatory cytokine produc-
tion and recruitment of several cell types to the lungs,
including cells of the innate immune response, such as
neutrophils and macrophages [3], as well as those of
adaptive immune response, namely T and B lympho-
cytes [4,5]. CD8
+ T cells are regarded as a hallmark cell
of COPD, and are increased in both the central [6] and
peripheral [7] airways of COPD patients. CD8
+ T cells
found within the airways are generally located within
the submucosa and invading the epithelium [8,9]. Unfor-
tunately, the role of CD8
+ T cells in COPD and the
mechanisms by which they are recruited to the lung are
still generally unknown. While it can be speculated that
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damaged lung, they could also contribute towards pro-
tecting the lung by sensing invading microbes and using
their cytotoxic abilities to eliminate infected cells.
Toll-like receptors (TLR), a key component of the
innate immune system, sense foreign microbes via
pathogen-associated molecular patterns. Although lar-
gely found on innate immune and structural cells
[10,11], TLRs are also present on T cells, thereby contri-
buting to the adaptive immune response [12-15]. TLR4,
which recognizes gram-negative bacteria, and TLR9,
which binds unmethylated CpG motifs, are two well-stu-
died TLRs. Activation of TL4 or TLR9, results in signal
transduction cascades involving downstream pathways
including nuclear factor of kappa B (NF-B) and JUN
N-terminal kinase (JNK) [16]. This ultimately results in
the production of inflammatory cytokines such as IL-1b,
IL-6, IL-8, TNFa and IL-10 which can modulate inflam-
matory responses [17-19].
There is growing interest in the potential role of TLRs
in COPD pathogenesis, [20,21] including the relation-
ship between cigarette smoke exposure and the expres-
sion of TLRs on epithelial cells [22,23]. In our study, we
investigated the expression of TLR4 and TLR9 on CD8
+
T cells, an important cell type in COPD pathogenesis.
We report for the first time increased expression of
TLR4 and TLR9 on CD8
+ T cells in lung tissue of
COPD patients compared to control subjects. Moreover,
our data further demonstrates that cigarette smoke
exposure induces TLR4 and TLR9 expression on CD8
+
T cells, which results in increased production of cyto-
kines, including IL-1b, IL-6, IL-10, IL-12p70, TNFa and
IFNg. Cigarette smoke activation of TLRs on CD8
+ T
cells and the resulting increased cytokine production
represents a mechanism by which CD8
+ T cells can
contribute to the pathogenesis of COPD.
Materials and methods
Study subjects
Endobronchial biopsies from eight COPD patients and
five aged-matched control subjects were received from
the Tissue Bank of the Respiratory Health Network of
the FRSQ, MUHC site. Peripheral blood was obtained
from nine COPD patients and eight control subjects
recruited at the Montreal Chest Institute. Each partici-
pant gave a total of 20 ml of peripheral blood and
underwent spirometry. Control subjects represented
healthy volunteers, either non-smokers or ex-smokers,
with normal lung function. Participant details can be
found in Table 1. This study was reviewed and approved
by The Biomedical C Research Ethics Board of the
Montreal Chest Institute, and written informed consent
was obtained from all subjects.
Immunostaining
Endobronchial biopsies were taken from the segmental
and subsegmental carinas of the right upper lobe and
immediately fixed in paraformaldehyde. Biopsies were
then embedded in paraffin and cut into 5 μm sections.
T h es e c t i o n sw e r ed e - p a r a f f i n ized in xylene, rehydrated
in ethanol and washed with PBS. Antigen retrieval was
performed using citrate buffer (pH 6); the sections were
permeabilized with 0.2% Triton X-100 (in PBS) and
then incubated with 5% hydrogen peroxide (in PBS).
After washing, the sections were blocked with Universal
Blocking Solution (Dako, Burlington, ON) for 30 min-
utes. Slides were incubated overnight at 4°C with a rab-
bit polyclonal IgG antibody against TLR4 or TLR9 (1.25
μg/ml; Abcam, Cambridge, MA). Slides were then incu-
bated with a biotinylated secondary antibody raised in
goat (1:100), followed by incubation with SA-HRP (Vec-
tor Laboratories, Burlington, ON). The immunostainings
were developed using the Liquid DAB+ Substrate Chro-
mogen System (Dako) according to the manufacturer’s
instructions and counterstained with hematoxylin and
lithium carbonate. Within the submucosa, the number
of immune cells positive for TLR4 or TLR9 were quanti-
fied and expressed as the number of positive immune
cells per square millimeter of subepithelium.
Table 1 Characterization of smoking status and
demographics of COPD patients and control subjects
Control COPD
Biopsy (n = 5) (n = 8)
Age (years) 54.8 ± 7.16 65.0 ± 17.33
Sex (M:F) 4:1 6:2
FEV1 (L) 3.69 ± 0.89 2.31 ± 0.84
FEV1/FVC (ratio) 0.83 ± 0.01 0.56 ± 0.08
GOLD Stage (I/II/III/IV) 0/0/0/0 3/3/2/0
Smoking History
Pack Years 3.4 ± 4.77 38.25 ± 14.76
Current smokers 0 5
Ex-smokers 2 3
Non-smokers 3 0
Blood (n = 8) (n = 9)
Age (years) 59.86 ± 7.15 64.63 ± 4.44
Sex (M:F) 5:3 6:3
FEV1 (L) 3.14 ± 0.63 1.21 ± 0.570
FEV1/FVC 0.79 ± 0.03 0.59 ± 0.25
GOLD Stage (I/II/III/IV) 0/0/0/0 0/4/4/0
Smoking History
Pack Years 13.59 ± 24.33 62.06 ± 29.67
Current smokers 0 1
Ex-smokers 4 8
Non-smokers 4 0
FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity
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+ cells, double
immunofluorescence was performed on endobronchial
biopsies embedded in OCT. Blocks were cut into 5 μm
sections and fixed with 70% ethanol for 30 seconds.
After washing with PBS, sections were permeabilized
and blocked as above. Sections were incubated overnight
at 4°C with a monoclonal IgG1 CD8 antibody (clone
C8/144B, Dako) at a concentration of 2 mg/ml. After
washing, the sections were incubated with a rabbit anti-
mouse AlexaFluor 555 (Invitrogen, Carlsbad, CA) sec-
ondary antibody for 1 hour in the dark at a concentra-
tion of 5 μg/ml. Next, the sections were incubated with
either the TLR4 or TLR9 antibody as described above
for 2 hours at room temperature. A goat anti-rabbit
AlexaFluor 488 (Invitrogen) secondary antibody was
used at a concentration of 5 μg/ml for 1 hour in the
dark. Sections were then washed and mounted using
PermaFluor™ Aqueous Mounting Medium (Thermo
Scientific, Waltham, MA). The absolute numbers of the
single- and double-stained cells were counted and
results were expressed as the percentage of CD8
+ T
cells expressing TLR4 or TLR9. All slides were imaged
using the Image-Pro Plus 6.2 system (Media Cyber-
netics, Bethesda, MD).
Peripheral blood mononuclear cell isolation and culture
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from the peripheral blood using Ficoll-Paque Plus
(GE Healthcare, Baie D’Urfé, QC). Cells were main-
tained in RPMI-1640 medium (Thermo Scientific) sup-
plemented with 10% v/v fetal bovine serum, L-
glutamine, penicillin, streptomycin, sodium pyruvate,
and HEPES and incubated at 37°C with 5% CO2.
Flow cytometry cell staining of PBMC
PBMCs were first incubated with intravenous immu-
noglobulin to prevent any non-specific binding. Cells
were then stained with an AlexaFluor 488-conjugated
mouse IgG2a antibody against TLR4, clone HTA125
(AbDSerotec, Kidlington, Oxford), or with a FITC-
conjugated mouse IgG2a antibody against TLR9, clone
5G5 (Abcam). All cells were stained with a CD8 anti-
body conjugated to APC, mouse IgG1,c l o n eR P A -
T8 (BD Pharmingen™, Mississauga, ON,) and a CD3
antibody conjugated to PE, mouse IgG1,c l o n e
UCHT1 (BD Pharmingen™). All corresponding iso-
type control antibodies were used. Cells stained for
TLR9 were permeabilized with Cytofix/Cytoperm (BD
Pharmingen™). A total of 25,000 events were
acquired by flow cytometry (FACSCalibur, BD
Bioscience) and analyzed using CellQuest™ Pro Soft-
ware. Data are presented as the percentage of posi-
tively stained cells for each subject.
CD8
+ T cell isolation and cigarette smoke condensate
treatment
CD8
+ T cells were isolated from PBMCs using the CD8
+
T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach,
DE) according to the manufacturer’s protocol. Briefly,
PBMCs were suspended in buffer (PBS containing 0.5%
w/v BSA and 2 mM EDTA, pH 7.2) and incubated with
a biotin-antibody cocktail containing antibodies against
CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123,
TCR g/δ and CD235a for 10 minutes at 4°C. Next, a
microbead-conjugated antibody against CD14 and biotin
was added for 15 minutes at 4°C. The cell suspension
was separated using LS columns with the Quadro-
MACS™ (Miltenyi Biotec) cell separator. The enriched
CD8
+ T cells passed through the column and were col-
lected. The CD8
+ T cell purity was ≥ 95% as confirmed
by flow cytometry staining (data not shown).
Once purified, the CD8
+ T cells were incubated with
cigarette smoke condensate (CSC), which was received as
a gift from Imperial Tobacco Canada, generated as pre-
viously reported [24]. The CD8
+ T cells were treated
w i t hC S Ca te i t h e r1 0o r5 0μg/ml for 24 hours. CD8
+ T
cells were also pretreated with or without a TLR4 neutra-
lizing antibody (10 μg/ml; clone HTA125, eBioscience,
San Diego, CA) or chloroquine (20 μg/ml; Invivogen, San
Diego, CA) for 1 hour followed by CSC at 50 μg/ml for
24 hours. Cells receiving DMSO were used as the control
as DMSO was the solvent for the CSC.
Protein quantification and immunoblotting
CD8
+ T cells were lysed in 100 μL of lysis buffer (50 mM
Tris-HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (v/v)
Triton x-100, 1 mM sodium orthovanadate, 5 mM sodium
pyrophosphate, 50 mM sodium fluoride, 0.27 M sucrose, 5
mM sodium pyrophosphate decahydrate and protease
inhibitors). Protein concentrations were quantified using
the BCA Protein Assay Kit (Thermo Scientific) according
to the manufacturer’s instructions. Fifty micrograms of
protein were boiled and separated on a 10% Pro-Pure
Next Gel with Pro-Pure Running Buffer (Amresco, Solon,
OH). After transferring proteins to nitrocellulose, mem-
branes were blocked for 1 hour at room temperature in
Odyssey Blocking Buffer (Li-Cor Biosciences, Lincoln,
NE). Blots were then incubated with anti-TLR4 antibody
(H-80; Santa Cruz, Santa Cruz, CA) at a concentration of
0.2 μg/ml or anti-TLR9 antibody (Abcam) at a concentra-
tion of 1 μg / m lo v e r n i g h ta t4 ° C .G o a ta n t i - r a b b i tI g G
(DyLight™800, Thermo Scientific) antibody was applied
for 1 hour in the dark at room temperature (1:15,000).
The signal was detected and quantified using a Li-Cor
Odyssey imaging system. All samples were normalized to
GAPDH (Millipore, Billerica, MA) and expressed as a
ratio relative to the DMSO sample.
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Supernatants were collected 24 hours after CD8
+ T
cells were treated with CSC and stored at -80°C until
used. The Human Pro-Inflammatory 7-Plex Tissue
Culture Kit was purchased from Meso Scale Discovery
(Gaithersburg, MD) and used according to the manu-
facturer’s protocol. The kit allowed for the quantifica-
tion of IL-1b, IL-6, IL-8, IL-10, IL-12p70, TNFa,a n d
IFNg from the cell supernatants using the SECTOR
®
Imager 2400. The lower limits of detection for this
plate were as follows: IL-1b, 0.0199 pg/ml; IL-6, 0.0158
pg/ml; IL-8, 0.0125 pg/ml; IL-10, 0.0794 pg/ml; IL-
12p70, 0.0199 pg/ml; TNFa, 0.3162 pg/ml, IFNg,0 . 0
pg/ml. The upper limit of detection was 10,000 pg/ml
for all cytokines.
Statistical analysis
For statistical analysis between two groups, a t-test was
used. Comparison between more than two groups was
performed by ANOVA, followed by a Bonferonni multiple
comparison test. A p-value of < 0.05 was considered statis-
tically significant (*p < 0.05; **p < 0.01; ***p < 0.0001). Data
are expressed as mean ± standard error of mean.
Results
TLR4 and TLR9 are expressed in COPD patients and
control subjects
Activation of TLRs can lead to the production of pro-
inflammatory mediators, many of which are increased in
COPD. However, there is little information on the
expression of TLR4 or TLR9 in the lungs of COPD
patients. Therefore, we first examined the expression of
TLR4 and TLR9 by immunohistochemistry in endo-
bronchial biopsies from COPD patients and control sub-
jects. TLR4 is expressed in the airway epithelium and
inflammatory cells in both healthy controls (Figure 1A)
as well as COPD patients (Figure 1B). In addition,
immunoreactivity of TLR9 was also found in the epithe-
lium and the immune cells within the subepithelial layer
in both control subjects (Figure 1C) and patients with
COPD (Figure 1D). The epithelium was scored accord-
ing to the extent of staining, thus the percentage of
epithelial cells showing positive immune reactivity.
There was no significant difference between controls
and COPD patients in the percentage of the epithelial
cells expressing TLR4 (Figure 2A) or TLR9 (Figure 2B).
In order to further quantify the staining in the sube-
pithelium, the number of positive immune cells per
square millimeter were counted from both COPD and
control biopsies for each of the TLRs of interest. There
was also no significant difference in the number of
immune cells expressing TLR4 (Figure 2C) or TLR9
(Figure 2D) in COPD biopsies compared to control
biopsies.
Co-localization of TLR4 and TLR9 on lung CD8
+ T cells in
COPD
Although the total lung expression of TLR4 and TLR9 did
not differ significantly between COPD patients and control
subjects, we wanted to examine the expression of TLR4
and TLR9 more closely in lung CD8
+ T cells. Therefore,
we performed immunofluorescence staining on endobron-
chial biopsies obtained from both COPD and control sub-
jects. Slides were stained for the presence of CD8
+ T cells,
(Figures 3A, D), and stained with either TLR4 (Figure 3B)
or TLR9 (Figure 3E) antibodies. An overlay of the images
shows co-localization of CD8 immunoreactivity and TL4
and TL9 positive cells (Figures 3C, F).
Quantification of the staining was performed by
counting the absolute numbers of single-stained CD8
+ T
cells compared to the double-stained CD8
+ T cells,
resulting in a percentage of CD8
+ T cells which express
TLR4 and TLR9. In the lung tissue of COPD patients,
there was a significant increase in the percentage of
CD8
+ T cells expressing TLR4 (Figure 4A) (p < 0.0001)
and TLR9 (Figure 4B) (p < 0.0001) when compared to
control subjects. COPD patients had approximately 90%
of their CD8
+ T cells co-expressing TLR4 and TLR9.
The number of cells co-expressing CD8 and TLR4 or
TLR9 was substantially lower in control subjects com-
pared to COPD patients, with less than 20% of CD8
+ T
cells expressing TLR4 or TLR9.
Expression of TLR4 and TLR9 on peripheral blood
mononuclear cells
Next, we wanted to investigate TLR4 and TLR9
expression in peripheral blood to observe if the
A   B  
C   D 
Figure 1 TLR4 and TLR9 are expressed in lung tissue.
Endobronchial biopsy tissue sections from COPD patients and control
subjects were processed by immunohistochemistry as described in
Materials and Methods. Representative examples show similar
immunoreactivity for TLR4 in the epithelium and inflammatory cells of
control subjects (A) and COPD patients (B). TLR9 was also expressed at
comparable levels in the epithelium and inflammatory cells in healthy
controls (C) and COPD patients (D). All magnifications are 200×.
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Page 4 of 13expression was similar to that of the lung. Peripheral
blood mononuclear cells (PBMC) were isolated and
stained with TLR4 and TLR9 antibodies. Flow cytome-
try was used to determine that COPD patients had a
significantly higher percentage of total PBMCs which
e x p r e s s e dT L R 4( F i g u r e5 A )( p<0 . 0 5 )a n dT L R 9( F i g -
ure 5B) (p < 0.05) compared to aged-matched control
subjects. To then determine if the PBMCs expressing
TLR4 or TLR9 included CD8
+ T cells, we stained the
PBMCs with CD8, TLR4 or TLR9 and CD3. A CD3
antibody was used to ensure that the population of
analyzed cells consisted of true T cells expressing CD8.
It was found that the percentage of CD8
+ T cells
which expressed TLR4 (Figure 5C) and TLR9 (Figure
5D) were not statistically different between COPD
patients and control subjects. In addition, the overall
expression of TLR4 and TLR9 was quite minimal on
peripheral blood CD8
+ T cells. This indicates that, in
contrast to what was observed in the lungs of COPD
patients, CD8
+ T cells do not greatly contribute to
TLR expression in the blood. While approximately
90% of the COPD lung CD8
+ T cells expressed these
receptors, this was only observed in about 2% of per-
ipheral blood CD8
+ T cells. This raises the possibility
that there may be a factor in the lungs of COPD
patients not found within in the blood, which can
induce TLR4 and TLR9 expression on CD8
+ T cells.
Furthermore, this factor would also have to be absent
from lungs and blood of control subjects as these sub-
jects had low TLR expression in general.
Cigarette smoke condensate upregulates TLR4 and TLR9
protein
Our findings led us to speculate that cigarette smoke may
be the contributing factor that can induce TLR4 and
TLR9 expression on CD8
+ T cells. Cigarette smoke is the
Control COPD
0
1
2
3
4
5
S
c
o
r
e
 
o
f
 
T
L
R
4
-
s
t
a
i
n
e
d
 
e
p
i
t
h
e
l
i
u
m
Control COPD
0
1
2
3
4
5
S
c
o
r
e
 
o
f
 
T
L
R
9
-
s
t
a
i
n
e
d
 
e
p
i
t
h
e
l
i
u
m
Control COPD
0
200
400
600
800
N
o
.
 
o
f
 
T
L
R
4
+
 
c
e
l
l
s
/
m
m
2
Control COPD
0
200
400
600
N
o
.
 
o
f
 
T
L
R
9
+
 
c
e
l
l
s
/
m
m
2
A B 
C D 
Figure 2 Quantification of TLR4 and TLR9 in COPD and control subjects. The degree of epithelial staining of TLR4 (A) and TLR9 (B) were
scored according to a scale (1 = no staining; 5 = 100% staining) following immunostaining. The numbers of the positively stained immune cells
were also counted, and the area of the tissue was measured. There was no significant difference in the percentage of TLR4- (A) or TLR9- (B)
stained epithelium between the two groups. There was also no significant difference in the total number of inflammatory cells expressing TLR4
(C) and TLR9 (D) between the control group and COPD patients, when expressed as cells/mm
2 tissue.
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Page 5 of 13primary risk factor for COPD, and considering the loca-
tion of CD8
+ T cells within the lung tissue, one would
expect that these cytotoxic cells are exposed to smoke.
Cigarette smoke exposure would also explain the lack of
co-localization found in the peripheral blood. To test this
hypothesis, CD8
+ T cells isolated from the peripheral
blood of COPD patients were treated with cigarette smoke
condensate (CSC) for 24 hours, mimicking the effects of
cigarette smoke exposure to the lungs. Cytotoxicity was
determined using trypan blue staining to demonstrate that
greater than 80% of cells remained viable at concentrations
of CSC up to 50 μg/ml (data not shown); this concentra-
tion approximates human exposures [25-27].
TLR4 and TLR9 gene expression was assessed by qRT-
P C R ,a n dt h e r ew a sn os i g n i f i c a n tc h a n g ei nT L R 4o r
TLR9 expression after 24 hours of CSC exposure (data not
shown). A similar finding was previously observed when
epithelial cells were treated with cigarette smoke [22]. In
A  C  B 
D E F 
Figure 3 Lung CD8
+ T cells express TLR4 and TLR9 in COPD patients. Representative immmunofluorescent images from frozen
endobronchial biopsies of COPD patients demonstrate the co-localization of CD8 (red fluorescence, panels A and D) and TL4 (green
fluorescence, panel B) or TLR9 (green fluorescence, panel E). The merged images show CD8
+ T cells expressing TLR4 or TLR9 (arrows, panels C
and F, respectively). All magnifications are 400×.
Control COPD
0
20
40
60
80
100 ***
%
 
o
f
 
C
D
8
+
T
 
c
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
T
L
R
4
Control COPD
0
20
40
60
80
100 ***
%
 
o
f
 
C
D
8
+
T
 
c
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
T
L
R
9
A B 
Figure 4 Quantitative analysis of the number of CD8
+ T cells expressing TLR4 or TLR9 in endobronchial biopsies. The absolute numbers
of the singled-stained CD8
+ T cells were counted and compared to the absolute numbers of CD8
+ T cells expressing TLR4 or TLR9 from COPD
patients (n = 6) and healthy controls (n = 5). The percentage of CD8
+ T cells expressing TLR4 (A) was significantly higher in COPD patients
(92.76 ± 1.18) compared to control subjects (14.38 ± 2.00). The percentage of CD8
+ T cells expressing TLR9 (B) was also significantly increased in
COPD patients (86.88 ± 0.51) compared to healthy controls (17.97 ± 3.74). Data are represented as mean ± SEM. *** indicate p-values < 0.0001.
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Page 6 of 13contrast, the expression of both TLR4 (Figure 6A, B) and
TLR9 (Figure 6A, C) protein was significantly increased (p
< 0.05) from baseline after a CSC exposure of 50 μg/ml,
suggesting these receptors are post-transcriptionally regu-
lated during CSC treatment.
CSC induces cytokine production from CD8
+ T cells
Next, we wanted to investigate the activation of CD8
+ T
cells by CSC to induce cytokine production. COPD- and
CD8-associated cytokines were measured in the superna-
tants of peripheral blood CD8
+ T cells treated with CSC,
DMSO or medium for 24 hours. There was no change in
the cytokine production between the cells given media
alone or those treated with DMSO. However, there was a
significant increase in IL-1b, IL-10, IL-12p70, TNFa and
IFNg (Figures 7A, D-F) (p < 0.05) at the highest concentra-
tion (50 μg/ml) of CSC when compared to the DMSO-
treated cells, while IL-6 was only significantly different
between the two smoke concentrations (Figure 7B). There
w a sn oc h a n g ei nI L - 8p r o d u c t i o n( F i g u r e7 C ) .I ts h o u l d
be noted that the concentrations of all cytokines released
was relatively low, suggesting that CD8
+ T cells may lack
the ability to secrete significant levels of cytokines in
COPD. However, these cytokine values correspond to
what is observed in the bronchoalveolar lavage fluid of
patients with bronchiectasis, another type of chronic lung
disease [28]. The significant increase in cytokine produc-
tion at 50 μg/ml cannot be ignored and may be critical to
the inflammatory setting. The increased expression of
TLR4 and TLR9 on CD8
+ T cells, concomitant with CSC-
induced release of pro-inflammatory cytokines, suggests
that the CSC is activating the TLR pathways to induce the
aforementioned cytokines.
Blocking the TLR4 and TLR9 pathways inhibits cytokine
production
To determine if the CSC is inducing cytokine produc-
tion through the activation of TLR4 and TLR9, we
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Figure 5 The expression of TLR4 and TLR9 on CD8
+ T cells from peripheral blood. Peripheral blood mononuclear cells (PBMC) were
isolated from the peripheral blood of COPD patients (n = 7-9) and control subjects (n = 6-8). The percentage of cells positive for CD8, TLR4 and
TLR9 were determined by flow cytometry. TLR4 (A) and TLR9 (B) expression in PBMCs was significantly increased in COPD patients compared to
healthy controls. PBMCs were double-stained with CD8 and either TLR4 and TLR9 and expressed as the number of CD8
+ T cells expressing the
receptor. There was no significant difference in the percent of CD8
+ T cells expressing TLR4 (C) or TLR9 (D) in COPD patients vs. healthy controls.
Each data point represents an individual patient. * indicate p-values < 0.05.
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Page 7 of 13utilized well-described inhibitors of TLR4 [29] and
TLR9 [30]. One hour prior to CSC treatment (50 μg/
ml), CD8
+ T cells were treated with a TLR4 neutralizing
antibody (10 μg/ml) or chloroquine (20 μg/ml). Chloro-
quine prevents endosomal acidification and is a com-
monly-used TLR9 signaling inhibitor [31]. Chloroquine
significantly reduced CSC-induced TNFa production
(Figure 8A) (p < 0.0001). IL-10 production was signifi-
cantly reduced by blocking either the TLR4 or TLR9
pathways (Figure 8C) (p < 0.05). As was observed in Fig-
ure 7, there was no change in IL-8 production (Figure
8B). Also, inhibition of TLR4 or TLR9 did not signifi-
cantly reduce IL-1b, IL-6, IL-12p70 and IFNg (data not
shown). Collectively, our data suggest that CSC induces
cytokine production from CD8
+ T cells through the
activation of TLR4 and TLR9. This finding highlights
the potential importance of TLRs on CD8
+ T cells in
promoting inflammation in the lungs of COPD patients.
Discussion
During the past few decades, the mortality rate of
COPD has been steadily climbing and it is estimated
that COPD will become the third leading cause of mor-
tality by 2030 [32]. Therefore, current research efforts
are focusing on the cellular mechanisms of COPD in an
attempt to identify potential therapeutic targets. Current
pharmacological treatments include bronchodilators and
inhaled corticosteroids, which according to the TORCH
[33] and UPLIFT [34] clinical trials, could not prevent
the decline in lung function in these patients. It has
been speculated that inhibiting TLRs, key cellular targets
involved in initiating and maintaining an inflammatory
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Figure 6 TLR4 and TLR9 protein expression on CD8
+ T cells is upregulated by CSC.C D 8
+ T cells isolated from the peripheral blood of
COPD patients (n = 4-5) and treated with CSC (10 μg/ml or 50 μg/ml) or DMSO for 24 hours. A representative western blot nitrocellulose
membrane expressing TLR4, TLR9 and GAPDH (A). Western blot analysis revealed an increase in TLR4 (B) and TLR9 (C) protein expression with a
CSC treatment of 50 μg/ml. Individual samples were normalized to GAPDH and then expressed as a relative ratio of treated compared to DMSO
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Figure 7 CSC induces cytokine production from CD8
+ T cells. CD8
+ T cells from COPD patients (n = 10) were treated with CSC (10 μg/ml or
50 μg/ml), DMSO, or medium for 24 hours. The supernatants were collected and cytokine expression was examined using the Human
ProInflammatory 7-Plex Tissue Culture Plate from Meso Scale Discovery. There was no significant change in cytokine production between the
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Page 9 of 13response, could hinder the FEV1 decline and thus func-
tion as a therapy for COPD patients [35]. Inhibiting
TLR activation would reduce the production of cyto-
kines, thus dampening inflammation, and thereby poten-
tially improving lung function or at least stoping its
decline. Consequently, studies have investigated the
expression of TLRs on both immune and epithelial cells
in COPD [20,21,23,36]. There is some discrepancy
between whether TLRs are up or downregulated, how-
ever this seems to vary according to the cell type being
examined.
CD8
+ T cells are the hallmark cells of COPD and are
increased in the airways of these patients. Although it is
known that the cytotoxic potential of these cells is cor-
related to the FEV1 [37] and largely mediated by
perforin, [38], the role of CD8
+ T cells in the pathogen-
esis of COPD still remains unclear. Our study is the
first to investigate the role of TLR4 and TLR9 on CD8
+
T cells and we demonstrate the differential expression
of TLR4 and TLR9 on CD8
+ T cells from COPD
patients. Here, there were significantly more TLR4- and
TLR9-expressing CD8
+ T cells isolated from the lungs
of COPD patients compared to control subjects. Inter-
estingly, there was a clear difference between lung and
peripheral blood CD8
+ T cells in TLR expression.
Surprisingly, our initial results revealed that there was
no significant difference in TLR4 and TLR9 immunor-
eactivity in inflammatory cells between COPD and con-
trol lung tissue. Although there were fewer
inflammatory cells in our age-matched controls, almost
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Figure 8 Inhibitors of the TLR4 and TLR9 pathways reduce cytokine secretion from CD8
+ T cells. CD8
+ T cells were incubated for 1 hour
with or without a TLR4 neutralizing antibody (10 μg/ml) or chloroquine (20 μg/ml). Cells were then treated with either DMSO or CSC (50 μg/ml)
for 24 hours. The supernatants were analyzed for cytokine expression using Human ProInflammatory 7-Plex Tissue Culture Plate. (A) Chloroquine
significantly reduced CSC-induced TNFa expression. (B) IL-8 expression was not significantly increased by CSC, however chloroquine was able to
reduce IL-8 levels back to baseline values. (C) Blocking the TLR4 and TLR9 pathways significantly attenuated the CSC-induced production of IL-10.
Data are represented as mean ± SEM. * indicates p-values < 0.05; ** indicates p-values < 0.01 and *** indicates p-values < 0.0001.
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Page 10 of 13all the immune cells expressed TLR4/TLR9. Conse-
quently, with more cells in the COPD biopsies, fewer of
these cells expressed the receptors. The fact that we
observed no significant change may have been due to
the variability of our samples as well as our small sam-
ple population. It is rather difficult to recruit healthy
control subjects which match the age of our COPD
patients and are willing to undergo bronchoscopy.
Interestingly, we found that 90% of the lung CD8
+ T
cells expressed TLR4 and TLR9 in COPD patients, com-
pared to only approximately 20% in control subjects.
This indicates that there is a certain selectivity over
which cells express these receptors in the diseased state.
Under COPD conditions, the lung seems to function
similarly to the intestine; the cells expressing the recep-
tors are more specific, allowing TLR activation to
become more precise, perhaps to better control persis-
tent lung inflammation.
PBMCs from COPD patients showed increased TLR4
and TLR9 compared to control subjects. Monocytes are
known to both express TLRs [14] and increase in num-
ber during chronic inflammation, and may therefore
account for the elevated percentage of TLRs in PBMCs
in the COPD patients. Further studies focusing on speci-
fic cell types in PBMCs, would help to clarify which
cells are responsible for the increase. Contrary to the
lung, the percentage of peripheral blood CD8
+ T cells
expressing TLR4 or TLR9 was not significantly different
between COPD patients and control subjects. It may be
that peripheral blood CD8
+ T cells from COPD patients
may change receptor expression once they have
migrated to the lung. With approximately 2% of periph-
eral blood CD8
+ T cells expressing TLR4 or TLR9, we
speculate that a trigger induces an increase (approxi-
mately 90%) in the number of CD8
+ T cells that express
TLR4 and TLR9 in the lung. Due to the proximity of
CD8
+ T cells to the epithelium, it is probable that cigar-
ette smoke can cause TLR upregulation on CD8
+ T
cells. Cigarette smoke induces inflammation in a wide
variety of cell types, which may be mediated via activa-
tion of TLRs. In support of this, recent studies have
shown that cigarette smoke-induced inflammation is
both TLR4-dependent [39] and can induce TLR9
expression on neutrophils [40]. Here, we have demon-
strated that TLR4 and TLR9 are increased by cigarette
smoke exposure in CD8
+ T cells from COPD patients,
further demonstrating that components of cigarette
smoke are able to activate T cells.
It was interesting to note that CD8
+ T cells exposed
to cigarette smoke condensate (CSC) for 24 hours did
not change their TLR4 or TLR9 mRNA expression,
while the protein levels of both receptors were signifi-
cantly increased. These results are consistent with those
from epithelial cells, which when treated for 18 hours
with a 10% cigarette smoke medium did not significantly
change TLR mRNA expression despite an upregulation
in TLR4 protein expression [22]. When neutrophils
were exposed to smoke, TLR9 mRNA expression was
increased at 5 hours, but showed decreased expression
at 24 hours [40]. These results, combined with our data,
suggest that TLR expression may be post-transciption-
ally regulated in CD8
+ T cells.
As for the protein data, previous results have demon-
strated that LPS can induce TLR4 protein expression on
CD8
+ T cells [41], and ODN can induce TLR9 activa-
tion on CD8
+ T cells [42] as well as protein expression
in other cells, such as neutrophils [40]. We hypothesize
that the cigarette smoke is acting similarly by activating
TLR4 and TLR9.
It is widely known that TLR activation results in a sig-
nal transduction cascade that acts through several path-
ways including NF-Ba n dJ N K ,w h i c hs u b s e q u e n t l y
bind to target DNA sequences to induce cytokine
expression. We hypothesized that activation of TLR4
and TLR9 by cigarette smoke would induce cytokine
r e l e a s eb yC D 8
+ T cells. Using an established model of
in vitro cigarette smoke exposure, CD8
+ T cells exposed
to CSC significantly increased their levels of IL-1b, IL-6,
IL-10, IL-12p70, TNFa and IFNg,b u tn o tI L - 8 .
Although IL-8 expression is known to be increased in
COPD, our data suggest that CD8
+ T cells are not the
major source of pulmonary IL-8 production. Lympho-
cytes exposed to cigarette smoke also have negligible IL-
8 production compared to other peripheral blood cells
[43], suggesting that the high IL-8 levels found in the
lungs of COPD patients are likely derived from airway
epithelial cells [44]. In addition, it has previously been
reported that CD8
+ T cells exposed to LPS express
TNFa and IFNg in a dose-dependent manner [41], simi-
lar to our data. This implies that components in our
CSC are acting as TLR ligands, activating the receptors
and causing the release of cytokines. To further investi-
gate this, we used a TLR4 neutralizing antibody and
chloroquine, a TLR9 signaling inhibitor, to block both
of these pathways. Chloroquine significantly reduced
both TNFa and IL-10 production, whereas the TLR4
neutralizing antibody significantly inhibited IL-10. IL-10,
a potent anti-inflammatory cytokine, is known to inhibit
the synthesis of inflammatory cytokines, including
TNFa [45]. It would not be beneficial to block a path-
way that inhibits IL-10 release; however it should be
noted that regulatory T cells [46] and macrophages [47]
are the main producers of IL-10, not CD8
+ T cells.
Therefore, one would have to look at the effect of these
TLR inhibitors on these cells to fully understand how
the use of these inhibitors would affect anti-inflamma-
tory processes. Inhibiting TLR4 and TLR9 modestly
reduced the levels of IL-1b, IL-6, IL-8, IL-12p70 and
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Page 11 of 13IFNg, suggesting that other receptors play a role in the
global induction of inflammatory cytokines due to
smoke exposure. It is well-described that inflammatory
cytokines can be produced through several pathways
including, NF-B [48] and p38 MAP kinase [49]. It is
therefore not surprising that inhibiting only two of the
receptors would not suppress all cytokine release. How-
ever, our findings do highlight the importance of these
receptors once cigarette smoke has entered the lungs of
patients.
Conclusions
CD8
+ T cells are one of the most important cell types in
COPD. Considering the lack of knowledge concerning
the role these cells are truly playing in this disease, it is
important to fully understand the phenotype of the CD8
+ T cells which have migrated to the lungs of these
patients. We have clearly shown the distinction between
the CD8
+ T cells expressed in the peripheral blood and
those found in the lung int e r m so fT L R 4a n dT L R 9
expression. Furthermore, we demonstrated for the first
time that CSC is responsible for the upregulation of
these receptors on lung CD8
+ T cells and the resulting
cytokine expression. This increased cytokine expression
can cause the recruitment of other inflammatory cells to
the lung, further perpetuating the damage and inflam-
mation observed in COPD patients. Blocking these
receptors may prove to be useful in the future as a
potential therapy.
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